ABSTRACT

Alopecia areata and moderate to severe rheumatoid arthritis can both be treated with the new medication Baricitinib. In addition, it received FDA clearance in 2022 as the first immunomodulatory medication for the management of COVID-19 in hospitalised individuals who needed supplemental oxygen. A selective JAK inhibitor, it inhibits Janus Kinase 1 and Janus Kinase 2 reversibly. Baricitinib in bulk and formulation can be estimated using rapid, accurate, and affordable approaches. The reaction with the BM reagent and methanol as the diluent served as the basis for the development of the visible spectroscopic approach. 10 mg of the drug were dissolved in 1 mL of DMSO (dimethyl sulfoxide) to create the standard stock solution for the Visible spectroscopic technique, which was then made up with methanol. Methanol was used to make the succeeding dilutions, and the maximum wavelength was discovered to be 580 nm. The linearity was discovered to be between 10?g/mL-500?g/mL, with an excellent correlation value (r2) of 0.998. In the second method that is fluorometric method, Baricitinib standard drug solution and sample tablet solution was prepared by first dissolving the 10mg drug in 0.1N H2SO4 and then making it up using double distilled water. The different concentrations of puredrug in the range 2-16?g/ml and one sample solution were measured for the intensity in the fluorometer. The calibration curve was plotted and the sample’s unknown concentration was calculated from the plot. The calibration curve was found to be linear with r2 value obtained as 0.99. The technique was validated in accordance with ICH Q2 R (2) standards. The accuracy (%RSD 2.0) of the visible method was within acceptable limits. As a result, the established visual approach is sensitive, repeatable, and accurate. Keywords: Baricitinib, COVID-19, BM reagent, Visible spectroscopic method, fluorometric method
Publication date: 01/03/2026

https://ijbpas.com/pdf/2026/March/MS_IJBPAS_2026_10009.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.3.10009